Pharbil Waltrop GmbH is a 100% subsidiary of NextPharma GmbH and is subject to a profit transfer and control agreement. The company, based in Waltrop, conducts contract manufacturing, development and distribution of pharmaceutical products and is internally organized into three profit centers: Lohnherstellung, Development and Distribution. Its services include bulk production and packaging of hormonal and non-hormonal solids, creams/ointments and liquid products as well as analytical development services. The sales market is almost exclusively in Europe with a focus on Germany and Western Europe; customers include both generics manufacturers and companies marketing original products.
die Auftragsherstellung (Entwicklung, Produktion und Verpackung) von chemisch- und pflanzlich-pharmazeutischen, chemischen und chemisch-technischen Produkten aller Art einschließlich Medizinprodukten und die Distribution dieser Produkte im Auftrag sowie die Entwicklung von Arzneimitteln, Bearbeitung von Zulassungsanträgen, Beantragung und Handel mit Arzneimittelzulassungen, schließlich die Beteiligung an Unternehmen mit gleichem Wirtschaftszweck und Geschäfte ähnlicherr Art
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Recklinghausen Local Court, HRB 4455 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Ajeeth Enjeti | Geschäftsführer(in) | Amstelveen |
Source: German Commercial Register (Handelsregister) Recklinghausen Local Court, HRB 4455 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2006 | €20,950,100 | €0 | €13,809,504 | — |
| 2005 | €21,094,583 | €0 | €13,817,634 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Recklinghausen Local Court, HRB 4455 (as of 31 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €9,093,487 | 88.0% |
| Depreciation | €1,126,483 | 10.9% |
| Interest & Similar | €114,396 | 1.1% |
